AI-Enabled Drug Discovery and Clinical Trials Market Size, Share, By Offering (Software Solutions and Services), Therapeutic Area (Oncology, Cardiovascular Diseases, Nervous System Diseases, Respiratory Diseases, Infectious Diseases, and Others), Application (Data Aggregation and Analysis, Clinical Trials, Drug Design, Drug Characterization, and Biomarker Research), End-User (Biopharmaceutical Industry, Contract Research Organizations (CROs), Academic and Research Centers, and Others), and Region - Trends, Analysis, and Forecast till 2035

Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

North America is the region with the largest AI-enabled drug discovery and clinical trials market share by 69.52%. This is due to this region’s increased investments on research and development, its robust healthcare infrastructure, widespread implementation of AI-technology in medical development, and the presence of crucial AI technology companies such as Microsoft.

Asia Pacific is the region, which has the fastest growing market, during the forecast period. This is due to this region’s increasing investment in AI and biotechnology, supportive regulatory environments, developing AI technologies to accelerate drug discovery and clinical trials to address unmet medical needs, and collaborations research initiatives.